Federal Judge Orders FDA Review of Mifepristone, Telehealth Access Remains

Why it matters locally: This ruling has implications for abortion access in Pennsylvania, particularly for individuals in rural areas who rely on telehealth services. The continued availability of mifepristone via telemedicine during the FDA review ensures that current access levels are maintained while the legal challenge proceeds.

---

A federal judge has mandated that the Food and Drug Administration (FDA) undertake a safety review of mifepristone, a drug used in medication abortion. This ruling comes as part of an ongoing legal challenge concerning the drug's availability, specifically its distribution via telemedicine. The case, brought by the state of Louisiana, seeks to ban the use of mifepristone through telemedicine. The legal proceedings will continue after the FDA has completed its review of the drug's safety profile. For the time being, the ruling allows access to abortion via telemedicine to remain in place, preserving current practices while the FDA conducts its review and the Louisiana case continues to move through the legal system. The timeline and specific scope of the FDA review are currently undetermined.